Preclinical Evaluation of SLV-013: A Novel GPC1 Targeting ADC for the Treatment of Solid Tumors

• Providing strategic rationale for targeting GPC-1, overall biology and expression profiling across multiple cancer lineages and primary normal cells and tissues
• Developing GPC-1 targeting ADCs utilizing a proprietary hydrophilic and highly stable linker technology
• Unveiling the preclinical characterization of SLV-013, including the cell binding, internalization, and in vitro and in vivo efficacy data

Speakers:

Hao Liu

Senior Director - Drug Discovery & Cancer Biology

Solve Therapeutics, Inc.